Real-world comparative effectiveness of tofacitinib, tumour necrosis factor inhibitors, and interleukin 17 inhibitors among patients with axial spondylarthritis and psoriatic arthritis

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Data collection methods:
  Secondary use of data

Study drug and medical condition

• Name of medicine:
  XELJANZ
• Study drug International non-proprietary name (INN) or common name:
  TOFACITINIB
• Medical condition to be studied:
  Axial spondyloarthritis
• Additional medical condition(s):
  Psoriatic Arthritis

Study design details

• Main study objective:
  Primary objectives:; 1. To compare the proportion of AxSpA patients fulfilling effectiveness criteria within 6 months after initiating treatment with tofacitinib vs TNFi vs IL-17i among patients with at least 6 months of continuous enrollment after index date.; 2. To compare the proportion of b/tsDMARD-naïve PsA patients fulfilling effectiveness criteria within 6 months after initiating treatment with tofacitinib vs TNFi vs IL-17i among patients with at least 6 months of continuous enrollment after index date.; ; Secondary objectives:; 1. To compare the proportion of AxSpA patients fulfilling effectiveness criteria within 12 months after initiating treatment with tofacitinib vs TNFi vs IL-17i among patients with at least 12 months of continuous enrollment after index date.; 2. To compare the proportion of b/tsDMARD-naïve PsA patients fulfilling effectiveness criteria within 12 months after initiating treatment with tofacitinib vs TNFi vs IL-17i among patients with at least 12 months of continuous enrollment after index date. ; 3. Evaluate drug persistence (median time to therapy discontinuation) among AxSpA patients within 12 months of treatment with tofacitinib vs TNFi vs IL-17i among patients with at least 12 months of continuous enrollment after index date.; 4. Evaluate drug persistence (median time to therapy discontinuation) among b/tsDMARD-naive PsA patients within 12 months of treatment with tofacitinib vs TNFi vs IL-17i among the sample of patients with at least 12 months of continuous enrollment after index date.; 5. Evaluate health care resource utilization and cost data for AxSpA patients within 6 and 12 months of treatment with tofacitinib vs TNFi vs IL-17i among patients with at least 6 or 12 months of continuous enrollment after index date, respectively.